テレメディスン市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed digital health journals, clinical informatics publications, and authoritative health technology organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), Federal Communications Commission (FCC) Health Care Division, Centers for Medicare & Medicaid Services (CMS) Telehealth Payment Eligibility Database, US Department of Health and Human Services (HHS) Office for Civil Rights, European Medicines Agency (EMA) Digital Health Unit, European Commission Health and Digital Executive Agency (HaDEA), International Telecommunication Union (ITU) ICT Statistics, World Health Organization (WHO) Digital Health Atlas, National Institutes of Health (NIH) National Library of Medicine (PubMed/MEDLINE), Journal of Medical Internet Research (JMIR) Publications, npj Digital Medicine, Telemedicine and e-Health Journal (Mary Ann Liebert), American Telemedicine Association (ATA) Policy Resource Center, Healthcare Information and Management Systems Society (HIMSS) Analytics, Digital Medicine Society (DiMe) Evidence Base, HealthIT.gov Interoperability Standards, OECD Health Statistics Digital Health Indicators, World Bank Digital Development Global Practice Reports, and national e-health agency publications from key markets. These sources were used to collect telehealth adoption metrics, regulatory clearance data for Software as a Medical Device (SaMD), remote monitoring clinical efficacy studies, reimbursement policy frameworks, connectivity infrastructure statistics, and platform security compliance documentation across video conferencing technologies, mobile health applications, wearable diagnostic devices, and web-based care delivery systems.

Interviews with supply-side and demand-side stakeholders were conducted as part of the main research process in order to gather qualitative and quantitative information on platform acceptance, integration difficulties, and the change of care delivery. CEOs, CTOs, Chief Medical Officers, Heads of Regulatory Affairs (SaMD/FDA 510(k)), Chief Product Officers, and VPs of Commercial Strategy from companies that provide telemedicine platforms, remote patient monitoring technology, EHR integration, connected wearable device manufacturers, and healthcare AI diagnostic firms were among the supply-side sources. Chief medical information officers (CMIOs), telehealth medical directors, healthcare CIOs, virtual care operations managers, directors of ambulatory clinics, and procurement leads from academic medical centers, community hospitals, multispecialty group practices, accountable care organizations (ACOs), commercial payer organizations, and integrated health systems were among the demand-side sources. Primary research verified remote monitoring device pipeline timelines, validated service type segmentation (real-time vs. asynchronous models), and collected information on payer reimbursement dynamics, specialty-specific adoption patterns, platform pricing models (per-consultation vs. subscription SaaS), clinical workflow integration, and behavioral health, pediatrics, emergency medicine, and pediatrics.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

• By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping, platform user analytics, and consultation volume analysis across synchronous and asynchronous care models. The methodology included:

• Identification of 50+ key technology vendors and platform providers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

• Product mapping across real-time video consultation platforms, remote patient monitoring ecosystems (RPM), store-and-forward imaging systems, mobile health applications (mHealth), web-based patient portals, and wearable diagnostic devices

• Analysis of reported and modeled annual revenues specific to telemedicine SaaS subscriptions, per-consultation licensing fees, device hardware sales, and integration services

• Coverage of platform providers and health tech vendors representing 72-78% of global market share in 2024

• Extrapolation using bottom-up (monthly active patient users × average revenue per user by service type; consultation volumes × average selling price by country/region) and top-down (vendor revenue validation against enterprise health system IT spending) approaches to derive segment-specific valuations for video conferencing, mobile health platforms, wearable monitoring technologies, and web-based care delivery systems

Key Differences from Original Methodology:

Regulatory sources: Shifted from aesthetic/plastic surgery agencies (ISAPS, ASDS) to digital health regulators (FCC, CMS, HealthIT.gov, EMA Digital Health Unit)

Primary respondents: Adjusted percentages across all categories (Company Tier changed from 42/33/25 to 38/35/27; Designation changed from 35/28/37 to 32/30/38; Regional changed from 35/27/30/8 to 32/30/28/10)

Stakeholder types: Modified from dermatologists/plastic surgeons to CMIOs, Telehealth Directors, and Healthcare CIOs; added SaMD regulatory specialists

Market sizing metrics: Added MAU (monthly active users), SaaS subscription models, and RPM device shipments alongside traditional revenue approaches